Literature DB >> 17885558

Aldosterone excess and resistance to 24-h blood pressure control.

Eduardo Pimenta1, Krishna K Gaddam, Monique N Pratt-Ubunama, Mari K Nishizaka, Stacey S Cofield, Suzanne Oparil, David A Calhoun.   

Abstract

BACKGROUND: Aldosterone excess has been reported to be a common cause of resistant hypertension. To what degree this represents true treatment resistance is unknown.
OBJECTIVE: The present study aimed to compare the 24-h ambulatory blood pressure monitoring (ABPM) levels in resistant hypertensive patients with or without hyperaldosteronism.
METHODS: Two hundred and fifty-one patients with resistant hypertension were prospectively evaluated with an early-morning plasma renin activity (PRA), 24-h urinary aldosterone and sodium, and 24-h ABPM. Daytime, night-time, and 24-h blood pressure (BP) and nocturnal BP decline were determined. Hyperaldosteronism (H-Aldo) was defined as suppressed PRA (<1.0 ng/ml per h or <1.0 mug/l per h) and elevated 24-h urinary aldosterone excretion (>/= 12 mug/24-h or >/= 33.2 nmol/day) during ingestion of the patient's routine diet.
RESULTS: In all patients, the mean office BP was 160.0 +/- 25.2/89.4 +/- 15.3 mmHg on an average of 4.2 medications. There was no difference in mean office BP between H-Aldo and normal aldosterone status (N-Aldo) patients. Daytime, night-time, and 24-h systolic and diastolic BP were significantly higher in H-Aldo compared to N-Aldo males. Daytime, night-time, and 24-h systolic BP were significantly higher in H-Aldo compared to N-Aldo females. Multivariate analysis indicated a significant interaction between age and aldosterone status such that the effects of aldosterone on ambulatory BP levels were more pronounced with increasing age.
CONCLUSIONS: In spite of similar office BP, ABPM levels were higher in resistant hypertensive patients with H-Aldo. These results suggest that high aldosterone levels impart increased cardiovascular risk not reflected by office BP measurements.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885558     DOI: 10.1097/HJH.0b013e3282a9be30

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 2.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

3.  Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Dena E Rifkin; Ali R Khaki; Nancy S Jenny; Robyn L McClelland; Matthew Budoff; Karol Watson; Joachim H Ix; Matthew A Allison
Journal:  Am J Hypertens       Date:  2014-01-16       Impact factor: 2.689

Review 4.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 5.  [Epidemiology and etiology of therapy-resistant hypertension].

Authors:  C Schirpenbach; M Reincke
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

6.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

7.  Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.

Authors:  Lama Ghazi; Suzanne Oparil; David A Calhoun; Chee Paul Lin; Tanja Dudenbostel
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

Review 8.  Recent advances in the management of resistant hypertension.

Authors:  Athanasios J Manolis; Manolis S Kallistratos; Michalis Doumas; Stamatina Pagoni; Leonidas Poulimenos
Journal:  F1000Prime Rep       Date:  2015-01-05

Review 9.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16

10.  MicroRNA 21 and microRNA 155 levels in resistant hypertension, and their relationships with aldosterone.

Authors:  Sonat Pınar Kara; Gulsum Ozkan; Ahsen Yılmaz; Nergiz Bayrakçı; Savaş Güzel; Elif Geyik
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.